November 20, 2023
Azome Therapeutics’ groundbreaking peptide technology that blocks inflammasome activation was the subject of a talk given by Rashmin C. Savani, MBChB, Head of Scientific Advisory Board at the Biennial Meeting of the American Society for Matrix Biology held in Salt Lake City, October 22–25.
In his presentation, “Towards the Universality of TLR Signaling: Developing Novel Therapeutics,” Dr. Savani provided an overview of the research supporting the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform.
Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia. The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.